reSee.it Video Transcript AI Summary
In July, Under Secretary Cisneros acknowledged that the DMET data, the database, was functioning properly, and also acknowledged a specific finding: myocarditis rising by 151 percent. Building on that, I conducted an identical examination today, applying the same methodological approach: using a five-year average for context and comparison, and restricting the analysis to active duty personnel who are fixed-wing pilots and helicopter pilots. The purpose of this approach is to establish a consistent baseline and to focus on the subgroup defined by flight duties and active-duty status.
The results from this targeted analysis show several notable figures across different cardiovascular conditions. Hypertensive disease is observed at 36 percent. Ischemic heart disease is observed at 69 percent. Pulmonary heart disease is observed at 62 percent. Heart failure is observed at 973 percent. Other forms of heart disease are observed at 63 percent. Cardiomyopathy is observed at 152 percent.
These percentages reflect the comparison of the five-year average to the 2022 figures, restricted to fixed-wing pilots and helicopter pilots who are on active duty. The substantially elevated figure for heart failure, at 973 percent, stands out among the listed categories, while ischemic heart disease at 69 percent and cardiomyopathy at 152 percent also present relatively high values within this cohort. The hypertensive disease category at 36 percent and the pulmonary heart disease category at 62 percent indicate additional areas of notable prevalence within the same population subgroup. The “other forms of heart disease” category at 63 percent contributes to the overall picture of cardiovascular condition distribution in this specific active-duty, flight-crew population.
In summary, the today-conducted, five-year-average-based comparison, limited to active-duty fixed-wing and helicopter pilots, yields the following prevalence levels for selected cardiovascular conditions relative to 2022: hypertensive disease 36 percent; ischemic heart disease 69 percent; pulmonary heart disease 62 percent; heart failure 973 percent; other forms of heart disease 63 percent; and cardiomyopathy 152 percent. These findings align with the prior acknowledgment that myocarditis had risen significantly (151 percent) and extend the pattern of elevated cardiovascular indicators within the same targeted group.